TORONTO, Aug 03, 2021 (GLOBE NEWSWIRE) – Mountain Valley MD Holdings Inc. (the “Company” or “MVMD“) (CSE: MVMD) (FRA: 20MP) (OTCQB: MVMDF) is pleased to announce the appointment of Dr. Azhar Rana as the Company’s Medical Director (“Marketing director“).
Dr Rana brings to the Company nearly two decades of life sciences experience in clinical development, pre-launch and post-launch medical affairs, regulatory and business strategy, including 10 years of pharmaceutical leadership at Bristol Myers-Squibb. , Novo Nordisk and AstraZeneca.
During his pharmaceutical career, Dr. Rana has gained experience in the development, launch and lifecycle management of new therapies, leading and collaborating with teams in clinical operations and development, medical affairs. , regulatory affairs, quality and pharmacovigilance.
Dr. Rana created the North American Organization for Integrated Communications in Medical Health (imc Group), a globally recognized medical communications agency that supports pharmaceutical, biotechnology and medical device companies. As President and CEO, Dr Rana has led a large cross-functional medical marketing team, working with global companies and healthcare professionals at various stages of drug and device development. He brings extensive experience in a number of pathological fields including virology, oncology, inflammation and metabolic diseases.
Dr Rana received her medical degree from Aga Khan University and subsequently trained in internal medicine in the UK.
“I am extremely proud to welcome Dr. Rana to our leadership team at Mountain Valley MD and look forward to his immediate contribution to advancing our pipeline of new health and wellness applications,” said Dennis Hancock, President and CEO of Mountain Valley MD. “Dr. Rana’s extensive pharmaceutical and biotech experience comes at a critical time for MVMD as we continue to advance our science and solidify key technology license agreements.
The Company granted 1,000,000 options to Dr. Rana at an exercise price of $ 0.365 per share. The options are exercisable for a period of five years, 20% vest on the grant date, 30% on the 6-month anniversary following the grant date and the remaining 50% on the 12-month anniversary following the grant date. the date of grant.
“I am thrilled to join MVMD and look forward to working with the excellent management team here to help advance the many technology applications to commercialization in this next phase of planned growth,” said Dr. Rana. “The pursuit of the Company’s broad vision of more life across the global landscape is very compelling to me personally at this point in my career and I am honored that my legacy is working to support broad animal husbandry and human health initiatives. “
ABOUT MOUNTAIN VALLEY MD HOLDINGS INC
Mountain Valley MD is building a world-class biotechnology and life sciences company focused on the implementation of its patented Quicksome ™ oral drug formulation and delivery technologies and Quicksol ™ solubilization technology for macrocyclic lactones, in order to innovate cutting-edge products that are sought after around the world. .
MVMD’s proposal to provide Quicksome ™ formulations that have rapid onset, high bioavailability, low variability and precision dosing is central to the company’s success in key health and wellness categories. In keeping with its vision of “helping people live their best lives”, MVMD applies its Quicksome ™ and Quicksol ™ technologies to its groundbreaking work for advanced vaccine and pharmaceutical drug delivery as well as product development for drug management. pain, weight loss, energy, focus, sleep, anxiety and more.
The company’s patented Quicksome ™ desiccation technology uses advanced liposomes and other stabilizing molecules to encapsulate and formulate active ingredients into highly effective product formats that are consumed orally. The result is a new generation of product formulations capable of delivering vaccines, drugs and nutraceuticals to the body faster, with increased impact, efficiency and precision.
The Company’s patented Quicksol ™ solubilization technology covers all highly solubilized macrocyclic lactones (including the drugs Ivermectin and Selamectin). MVMD’s solubility technology applied to the drug Ivermectin is the only form in the world that uses only excipients currently approved by the United States Food and Drug Administration (FDA), making it a prime candidate for the drug. human injection and sublingual applications as well as much broader treatments for animal husbandry and pets due to its low viscosity.
For more information about the company and its contact details, visit www.mountainvalleymd.com.
SOURCE: Mountain Valley MD Holdings Inc.
CAUTION REGARDING FORWARD-LOOKING INFORMATION
Certain statements contained in this press release may constitute forward-looking information. Forward-looking information is often, but not always, identified by the use of words such as “anticipate”, “plan”, “estimate”, “expect”, “could”, “will”, “the”. intention ”,“ should ”, and similar expressions. Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking information.
The actual results of the Company could differ materially from those anticipated in this forward-looking information due to regulatory decisions, competitive factors in the industries in which the Company operates, economic conditions and other factors, many of which are beyond the scope of to the control of the company.
The Company makes forward-looking statements regarding the appointment of Dr. Rana. The Company believes that the expectations reflected in the forward-looking information are reasonable, but no assurance can be given that such expectations will prove to be correct and such forward-looking information should not be unduly relied upon. Any forward-looking information contained in this press release represents the Company’s expectations as of the date hereof and is subject to change after such date. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities legislation.